Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology

Core Insights - Celularity Inc. has developed a proprietary advanced biomaterial technology, specifically a tri-layer decellularized, dehydrated human amniotic membrane (DDHAM-3L), which serves as a novel cellular delivery system for ocular surface reconstruction [1][2][4] - The research published in the journal Regenerative Engineering and Translational Medicine highlights the potential of DDHAM-3L in supporting the proliferation and stemness of induced pluripotent stem cell (iPSC)-derived limbal stem cells (LSCs) for treating limbal stem cell deficiency (LSCD) and other ocular surface disorders [2][3] - The study indicates that iPSC-LSCs seeded on DDHAM-3L formed confluent cell sheets and exhibited a higher proliferation rate compared to controls, demonstrating its effectiveness as an advanced biomaterial [3][4] Company Overview - Celularity Inc. is focused on developing and commercializing advanced biomaterial products and placental-derived cell therapies, leveraging the unique biology of the postpartum placenta to address unmet global healthcare needs [5] - The company aims to advance its DDHAM-3L technology for broader clinical applications beyond ophthalmology, emphasizing its scalability and patient-specific benefits [4][5]